Frontlight ResearchEarly access
Spinal muscular atrophy trials in Belarus
1 trial · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleStudy of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
- Where
- Minsk
- Age
- Up to 240 days
- People
- 40 worldwide
- Run by
- Biocad
See details and how to joinNCT05747261